Delivery Order SPE2DR25D1100-SPE2DR26FEB4V
Award Date 5/27/26
Potential Completion Date 6/17/26
Potential Value $17K
Federal Agency
Ultimate Awardee
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- <p>The Defense Logistics Agency issued a $17,245.62 delivery order to Amerisourcebergen Drug Corp on May 20, 2026, for FOTIVDA 1.34 MG capsules (21-count unit).</p> <p>The order is issued under a DLA Troop Support Medical indefinite delivery contract supporting pharmaceutical supply to Defense Health Agency and military medical facilities. Place of performance is Conshohocken, PA. The order carries a firm fixed price and ultimate completion date of June 11, 2026.</p>
- The Defense Logistics Agency issued a $17,245.62 delivery order to Amerisourcebergen Drug Corp on April 29, 2026, for FOTIVDA 1.34 MG capsules (pharmaceutical supply). The order is issued under the DLA Troop Support Medical Indefinite Delivery Contract (SPE2DX series), which supports pharmaceutical prime vendor supply to Defense Health Agency and military medical facilities globally. Place of performance is Conshohocken, PA. The order has a firm fixed-price structure and an ultimate completion...
- The Defense Logistics Agency awarded a $15,953.54 delivery order to AmerisourceBergen Drug Corp for FOTIVDA 1.34 mg capsule supply (21-count units) on August 4, 2025, with an ultimate completion date of August 25, 2025. This firm fixed-price contract is not set-aside and represents a competitive award under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at thirty thousand eight hundred forty-one dollars and sixteen cents ($30,841.16) to Amerisourcebergen Drug Corporation for FOTIVDA 1.34 MG capsules. Under this firm fixed price contract, Amerisourcebergen will deliver twenty-one (21) capsules of the pharmaceutical product to a location in Conshohocken, Pennsylvania by August 24, 2023 in support of DLA programs. No major subcontractors or set aside designations were identified. This...
- The Defense Logistics Agency awarded a $31,192.36 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 4561598368 FOTIVDA 0.89 MG CAPSULE 21S. The prime contractor, Amerisourcebergen Drug Corporation Corporate Office Division, will deliver the requested pharmaceutical products to a location in Conshohocken, Pennsylvania by August 15, 2023. As a major component of the Department of Defense that manages global logistics operations for the military services, the Defense...
- The Defense Logistics Agency issued a $17,245.62 delivery order to Amerisourcebergen Drug Corp on March 19, 2026, for FOTIVDA 1.34 MG CAPSULE 21S pharmaceutical supply. The order was placed under the DLA Troop Support Medical indefinite delivery contract (SPE2DX), valued at up to $999,999,999.00 and running through December 2026. This prime vendor contract enables supply of pharmaceutical products and medical commodities to support military healthcare programs worldwide. Place of performance...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of the for-profit Amerisourcebergen Corporation. The contract, valued at $15,420.59, is for the delivery of FOTIVDA 1.34 MG CAPSULE 21S pharmaceutical products to Conshohocken, Pennsylvania. This delivery order is issued under a larger, single-award indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp with DLA, with a potential value up to...
- The Defense Logistics Agency awarded a delivery order under an undisclosed contract vehicle to AmerisourceBergen Drug Corporation for the supply of 21 capsules of the pharmaceutical FOTIVDA at 0.89 mg each. Valued at $15,596.18 with a firm fixed price, the order is to be performed in Conshohocken, Pennsylvania between August 22nd and September 13th, 2023. As a major provider of medical supplies and pharmaceuticals to the U.S. military, this order for cancer treatment medication supports the...
- Defense Logistics Agency Troop Support Medical awarded a $15,420.59 firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for FOTIVDA 1.34 MG CAPSULE 21S. The contract has no set-aside designation. Performance will occur in Conshohocken, Pennsylvania, with all items to be delivered by November 8, 2023. As the Defense Logistics Agency supports the United States Armed Forces with supplies, this contract will provide needed...
- The Defense Logistics Agency awarded a $40,376.56 firm fixed-price delivery order to Amerisourcebergen Drug Corp on January 20, 2026, for the supply of FOTIVDA 1.34 milligram capsules (21 count). This non-competitive delivery order will be performed in Conshohocken, Pennsylvania, with an ultimate completion date of February 10, 2026. The award represents a task order against Amerisourcebergen's parent company, Cencora, Inc. (doing business as Amerisourcebergen), which holds a substantial...
- SPE2DR25D1100Indefinite Delivery Contract
- SPE2DR25D1100-SPE2DR26FEB4VDelivery Order
The Defense Logistics Agency issued a $17,245.62 delivery order to AmerisourceBergen Drug Corp on May 27, 2026, for FOTIVDA 1.34 MG capsules (21-count). Place of performance is Conshohocken, PA. The order is firm fixed price with an ultimate completion date of June 17, 2026. No set-aside was used. AmerisourceBergen Drug Corp operates as a subsidiary of Cencora, Inc. and holds a single-award indefinite delivery contract (SPE2DX) with the Defense Logistics Agency for the Pharmaceutical Prime Vendor Global Program Generation V, valued at $4.999 million through December 2036.
Generated 8/25/26, 10:02 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.2k | 5/26/26 |